Patents by Inventor Michael BALTEZOR

Michael BALTEZOR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucocorticoid “nintedanib” particles and their use
    Patent number: 11931368
    Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 19, 2024
    Assignee: CRITITECH, INC.
    Inventors: Michael Baltezor, Matthew McClorey, Joseph S. Farthing, Mark Williams, Jacob Sittenauer
  • Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
    Patent number: 11918691
    Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: March 5, 2024
    Assignee: CRITITECH, INC.
    Inventors: Gere S. Dizerega, Michael Baltezor, Sam Campbell, Charles J. Decedue, Matthew McClorey, Holly Maulhardt
  • NICLOSAMIDE PARTICLES AND USES THEREOF
    Publication number: 20230414510
    Abstract: The disclosure provides compositions and methods for use of compositions that include particles comprising at least 30% niclosamide by weight, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the particles have one or more of: (i) a mean bulk density (not tapped) of less than 0.40 g/cm3; 00 a mean tapped density of less than 0.55 g/cm 3 ; and/or (in) a specific surface area (SSA) of at least 3.6 m2/g.
    Type: Application
    Filed: September 8, 2021
    Publication date: December 28, 2023
    Inventors: Michael BALTEZOR, Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Aranza Barreda ABARCA
  • Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles
    Publication number: 20230372234
    Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
  • Sorafenib particles and uses thereof
    Publication number: 20230364021
    Abstract: Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m, as are methods for their use, and methods for making such particles.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 16, 2023
    Inventors: Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
  • Niraparib particles and uses thereof
    Patent number: 11738014
    Abstract: Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: August 29, 2023
    Assignee: Crititech, Inc.
    Inventors: Jacob Sittenauer, Aranza Barreda Abarca, Shelby Clark, Joseph Farthing, Mark Williams, Gere Dizerega, Michael Baltezor
  • Treatment of epithelial cysts by intracystic injection of antineoplastic particles
    Patent number: 11737972
    Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: August 29, 2023
    Assignee: CRITITECH, INC.
    Inventors: Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
  • Rucaparib particles and uses thereof
    Patent number: 11738029
    Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: August 29, 2023
    Assignee: CRITITECH, INC.
    Inventors: Jacob Sittenauer, Aranza Barreda Abarca, Shelby Clark, Joseph Farthing, Mark Williams, Gere Dizerega, Michael Baltezor
  • Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
    Publication number: 20230263731
    Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.
    Type: Application
    Filed: January 13, 2023
    Publication date: August 24, 2023
    Inventors: Gere S. DIZEREGA, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, Matthew MCCLOREY
  • Rucaparib particles and uses thereof
    Publication number: 20230142186
    Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 11, 2023
    Inventors: Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
  • Niraparib particles and uses thereof
    Publication number: 20230142591
    Abstract: Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 11, 2023
    Inventors: Jacob SITTENAUER, Aranza Barreda ABARCA, Shelby CLARK, Joseph FARTHING, Mark WILLIAMS, Gere DIZEREGA, Michael BALTEZOR
  • Treatment of Epithelial Cysts by Intracystic Injection of Antineoplastic Particles
    Publication number: 20230111288
    Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
    Type: Application
    Filed: October 12, 2022
    Publication date: April 13, 2023
    Inventors: Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
  • Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
    Patent number: 11583499
    Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: February 21, 2023
    Assignee: CritiTech, Inc.
    Inventors: Gere S. Dizerega, Michael Baltezor, Sam Campbell, Charles J. Decedue, Matthew McClorey
  • Treatment of epithelial cysts by intracystic injection of antineoplastic particles
    Patent number: 11523983
    Abstract: Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: December 13, 2022
    Assignee: CritiTech, Inc.
    Inventors: Gere S. diZerega, Michael Baltezor, Charles J. Decedue, Sam Campbell, Matthew McClorey, Marc Iacobucci, Holly Maulhardt
  • Lapatinib particles and uses thereof
    Publication number: 20220370355
    Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m.
    Type: Application
    Filed: July 14, 2022
    Publication date: November 24, 2022
    Inventors: Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
  • Sorafenib particles and uses thereof
    Publication number: 20220241257
    Abstract: The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m, methods for their use, and methods for making such particles.
    Type: Application
    Filed: July 21, 2021
    Publication date: August 4, 2022
    Inventors: Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
  • Treatment of Bladder Cancer by Local Administration of Taxane Particles
    Publication number: 20220096423
    Abstract: Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. Administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 31, 2022
    Inventors: Gere S. DIZEREGA, Michael BALTEZOR, Charles DECEDUE, Sam CAMPBELL, Matthew MCCLOREY
  • Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
    Publication number: 20220047513
    Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.
    Type: Application
    Filed: May 28, 2021
    Publication date: February 17, 2022
    Inventors: Gere S. DIZEREGA, Michael BALTEZOR, Sam CAMPBELL, Charles J. DECEDUE, Matthew MCCLOREY
  • Lapatinib particles and uses thereof
    Publication number: 20220023215
    Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m.
    Type: Application
    Filed: July 21, 2021
    Publication date: January 27, 2022
    Inventors: Jacob SITTENAUER, Joseph FARTHING, Mark WILLIAMS, Michael BALTEZOR, Gere DIZEREGA, Aranza Barreda ABARCA, Shelby CLARK
  • Taxane Particles and Their Use
    Publication number: 20210393569
    Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 23, 2021
    Inventors: Michael BALTEZOR, Joseph FARTHING, Jake SITTENAUER, Jahna ESPINOSA, Samuel CAMPBELL, Matthew MCCLOREY, Julia K. FISCHER, Mark D. WILLIAMS, Gary E. CLAPP